The 36-item short form health survey (SF-36) and Work Productivity and the Impairment (WPAI) questionnaire in panic disorder

Disease Management and Health Outcomes

Volumn 1, Issue 3, 1997, Pages 154-164

  Chirban, John T ^a   Jacobs, R Jake ^b,h   Warren, Jerry ^c   Ettigi, Prakash ^d   Sodomsky, Martin E ^e   Clarke, Jack F ^e   Meyerhoff, Allen S ^b   Reid Wilson, R ^e   Frank, Monica ^f   Abramson, Y M ^g  

^a CAMBRIDGE HOSPITAL   (United States)

^b Capitol Outcomes Research Inc   (United States)

^c Active Psychotherapeutics   (United States)

^d Panic Anxiety and Depression Center of Virginia   (United States)

^e Behavioural Consultants ^*

^f Behavioural Consultants   (United States)

^g Anxiety and Phobia Treatment Center   (United States)

^h Capitol Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000834390     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199701030-00005     Document Type: Article

References (54)

1. Marks IM. Fears and phobias. London: Heinemann, 1969
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51: 8-19
3. Ormel J, VonKorff M, Ustun TB, et al. Common mental disorders and disability across cultures. JAMA 1994; 272: 1841-8
4. Markowitz JS, Weissman MM, Ouellette R, et al. Quality of life in panic disorder. Arch Gen Psychiatry 1989; 46: 984-92
5. Edlund MJ, Swann AC. The economic and social costs of panic disorder. Hosp Community Psychiatry 1987; 38: 1277-9, 1288
6. Taylor CB, King R, Margraf J, et al. Use of medication and in vivo exposure in volunteers for panic disorder research. Am J Psychiatry 1989; 146: 1423-6
7. Coryell W, Noyes R, Clancy J. Excess mortality in panic disorder. A comparison with primary unipolar depression. Arch Gen Psychiatry 1982; 39: 701-3
8. Weissman MM, Klerman GL, Markowitz JS, et al. Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med 1989; 321: 1209-14
9. Allgulander C, Lavori PW. Excess mortality among 3302 patients with 'pure' anxiety neurosis. Arch Gen Psychiatry 1991; 48: 599-602
10. Hornig CD, McNally RJ. Panic disorder and suicide attempt: a reanalysis of data from the Epidemiologic Catchment Area Study. Br J Psychiatry 1995; 167: 76-9
11. Hollander E, Simeon D, Gorman JM. Anxiety disorders. In: Hales RE, Yudofsky SC, Talbott JA, editors. The American psychiatric press textbook of psychiatry. Washington, DC: American Psychiatric Press, 1994
12. Sherbourne CD, Wells KB, Judd LL. Functioning and well-being of patients with panic disorder. Am J Psychiatry 1996; 153: 213-8
13. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders. JAMA 1995; 274: 1511-7
14. Tesar GE, Rosenbaum JF. Successful use of clonazepam in patients with treatment-resistant panic disorder. J Nerv Ment Dis 1986; 174: 477-82
15. Spier SA, Tesar GE, Rosenbaum JF, et al. Treatment of panic disorder and agoraphobia with clonazepam. J Clin Psychiatry 1986; 47: 238-42
16. Liebowitz MR, Fyer AJ, Gorman JM, et al. Alprazolam in the treatment of panic disorders. J Clin Psychopharmacol 1986; 6: 13-20
17. Dunner DL, Ishiki D, Avery DH, et al. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986; 47: 458-60
18. Pyke RE, Greenberg HS. Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders. J Clin Psychopharmacol 1989; 9: 15-21
19. Sheehan DV, Raj AB, Harnett-Sheehan K, et al. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993; 88: 1-11
20. Wilkinson G, Balestrieri M, Ruggeri M, et al. Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders. Psychol Med 1991; 21: 991-8
21. Rizley R, Kahn RJ, McNair DM, et al. A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder. Psychopharmacol Bull 1986; 22: 167-72
22. Klerman GL. Treatments for panic disorder. J Clin Psychiatry 1992; 53 Suppl.: 14-9
23. Sheehan DV. Monoamine oxidase inhibitors and alprazolam in the treatment of panic disorder and agoraphobia. Psychiatr Clin North Am 1985; 8: 49-62
24. Tiffon L, Coplan JD, Papp LA, et al. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Psychiatry 1994; 55: 66-9
25. German JM, Liebowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7: 329-32
26. Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990; 10: 119-21
27. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993; 54 Suppl.: 3-15
28. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993; 54: 435-8
29. Shear MK, Maser JD. Standardized assessment for panic disorder research. A conference report. Arch Gen Psychiatry 1994; 51: 346-54
30. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83
31. McHorney CA, Ware JE, Raczek AE. The MOS 36-item short form health survey: II. Psychometric and clinical tests of validity in measuring physical and mental constructs. Med Care 1993; 31: 247-63
32. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health questionnaire: new outcome measure for primary care. BMJ 1992; 305: 160-4
33. McHorney CA, Ware JE, Rogers W, et al. The validity and relative precision of MOS short- and long-form health scales and Dartmouth COOP charts. Results from the medical outcomes study. Med Care 1992; 30 Suppl.: MS253-65
34. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and impairment instrument. Pharmacoeconomics 1993; 4: 353-65
35. Ware JE. SF-36 Health Survey: manual and interpretation guide. Boston (MA): The Health Institute, 1993
36. Ware JE. SF-36 Physical and Mental Health Summary Scales: a user's manual. Boston (MA): The Health Institute, 1994
37. Kazis LE, Andersen JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; S178-89
38. Cohen T. Statistics in medicine. Boston (MA): Little Brown & Co. Inc., 1974
39. Helmstadter CG, Principles of psychological measurement. New York (NY): Appleton-Century-Croft, Inc., 1964
40. Stephens MA. EDF statistics for goodness of fit and some comparisons. J Am Stat Assoc 1974; 69: 730-7
41. Miller Jr RG, Simultaneous statistical inference. New York (NY): McGraw-Hill, 1960
42. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA 1989; 262: 907-13
43. Gelberg L, Linn LS. Psychological distress among homeless adults. J Nerv Ment Dis 1989; 177: 291-5
44. Cleary PD, Epstein AM, Oster G, et al. Health-related quality of life among patients undergoing percutaneous transluminal coronary angioplasty. Med Care 1991; 29: 939-50
45. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with HIV infection. Med Care 1991; 29: 786-98
46. Katz JN, Larson MG, Phillips CB, et al. Comparative measurement sensitivity of short and longer health status instruments. Med Care 1992; 30: 917-25
47. Kurtin PS, Davies AR, Meyer KB, et al. Patient-based health status measures in outpatient dialysis: early experiences in developing an outcomes assessment program. Med Care 1992; 30 Suppl.: MS136-49
48. Wachtel T, Piette J, Mor V, et al. Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Intern Med 1992; 116: 129-37
49. Jenkinson C, Coulter A, Wright L. The Short Form 36 (SF-36) Health Survey Questionnaire: normative data for adults of working age. BMJ 1993; 306: 1437-40
50. Garratt AM, Ruta DA, Abdalla MI, et al. The SF-36 Health Profile: An outcome measure suitable for routine use within the NHS? BMJ 1993; 306: 1440-4
51. McHorney CA, Ware JE, Lu JFR, et al. The MOS 36-Item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66
52. McHorney CA, Kosinski M, Ware JE. Comparison of the costs and quality of norms for the SF-36 survey by mail versus telephone interview: results from a national survey. Med Care 1994; 32: 551-67
53. Thalji L, Haggerty CC, Rubin R, et al. 1990 Survey of Functional Health Status: final report. Chicago (IL): National Opinion Research Center, 1991
54. Nerenz DR, Repasky DP, Whitehouse FW, et al. Ongoing assessment of health status in patients with diabetes mellitus. Med Care 1992; 30 Suppl.: MS112-24